Dual-target CAR-T ‘very promising’ for advanced multiple myeloma
GC012F (Gracell Biotechnologies) is an autologous, genetically engineered, bispecific CAR-T that targets B cell maturation antigen (BCMA) and CD19 proteins on the surface of cancer cells. BCMA is universally expressed on malignant plasma cells and is a well-established target for multiple myeloma, while CD19 is expressed on both myeloma cells and their progenitor cells. The […]
